Loss of heterozygosity and DNA methylation affect germline fibroblast growth factor receptor 4 polymorphism to direct allelic selection in breast cancer

American Journal of Pathology

Volumn 177, Issue 6, 2010, Pages 2860-2869

  Zhu, Xuegong ^a,b   Zheng, Lei ^a,b   Asa, Sylvia L ^a,b   Ezzat, Shereen ^a,b  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AZACITIDINE; FIBROBLAST GROWTH FACTOR RECEPTOR 4;

ADULT; AGED; ALLELE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER GROWTH; CLINICAL ARTICLE; CONTROLLED STUDY; DNA METHYLATION; DNA POLYMORPHISM; GENE CONTROL; GENE FREQUENCY; GENETIC SELECTION; GERM LINE; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPH NODE METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SOMATIC MUTATION;

EID: 78650211213     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.2353/ajpath.2010.100509     Document Type: Article

References (43)

1. Givol D, Yayon A: Complexity of FGF receptors: genetic basis for structural diversity and functional specificity. FASEB J 1992, 6:3362-3369 (Pubitemid 23007101)
2. Yan G, Wang F, Fukabori Y, Sussman D, Hou J, McKeehan WL: Expression and transformation of a variant of the heparin-binding fibroblast growth factor receptor (flg) gene resulting from splicing of the exon at alternate 3′-acceptor site. Biochem Biophys Res Commun 1992, 183:423-430
3. Ornitz DM, Zu J, Colvin JS, McEwen DG, MacArthur CA, Coulier F, Gao G, Goldfarb M: Receptor specificity of the fibroblast growth factor family. J Biol Chem 1996, 271:15292-15297
4. Easton DF, Pooley KA, Dunning AM, Pharoah PD, Thompson D, Ballinger DG, Struewing JP, Morrison J, Field H, Luben R, Wareham N, Ahmed S, Healey CS, Bowman R, Meyer KB, Haiman CA, Kolonel LK, Henderson BE, Le Marchand L, Brennan P, Sangrajrang S, Gaborieau V, Odefrey F, Shen CY, Wu PE, Wang HC, Eccles D, Evans DG, Peto J, Fletcher O, Johnson N, Seal S, Stratton MR, Rahman N, Chenevix-Trench G, Bojesen SE, Nordestgaard BG, Axelsson CK, Garcia-Closas M, Brinton L, Chanock S, Lissowska J, Peplonska B, Nevanlinna H, Fagerholm R, Eerola H, Kang D, Yoo KY, Noh DY, Ahn SH, Hunter DJ, Hankinson SE, Cox DG, Hall P, Wedren S, Liu J, Low YL, Bogdanova N, Schurmann P, Dork T, Tollenaar RA, Jacobi CE, Devilee P, Klijn JG, Sigurdson AJ, Doody MM, Alexander BH, Zhang J, Cox A, Brock IW, MacPherson G, Reed MW, Couch FJ, Goode EL, Olson JE, Meijers-Heijboer H, van den OA, Uitterlinden A, Rivadeneira F, Milne RL, Ribas G, Gonzalez-Neira A, Benitez J, Hopper JL, McCredie M, Southey M, Giles GG, Schroen C, Justenhoven C, Brauch H, Hamann U, Ko YD, Spurdle AB, Beesley J, Chen X, Mannermaa A, Kosma VM, Kataja V, Hartikainen J, Day NE, Cox DR, Ponder BA: Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 2007, 447:1087-1093 (Pubitemid 47014426)
5. Hunter DJ, Kraft P, Jacobs KB, Cox DG, Yeager M, Hankinson SE, Wacholder S, Wang Z, Welch R, Hutchinson A, Wang J, Yu K, Chatterjee N, Orr N, Willett WC, Colditz GA, Ziegler RG, Berg CD, Buys SS, McCarty CA, Feigelson HS, Calle EE, Thun MJ, Hayes RB, Tucker M, Gerhard DS, Fraumeni JF Jr, Hoover RN, Thomas G, Chanock SJ: A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet 2007, 39:870-874
6. Meyer KB, Maia AT, O'Reilly M, Teschendorff AE, Chin SF, Caldas C, Ponder BA: Allele-specific up-regulation of FGFR2 increases susceptibility to breast cancer. PLoS Biol 2008, 6:e108
7. Ueno H, Gunn M, Dell K, Tseng A Jr, Williams L: A truncated form of fibroblast growth factor receptor 1 inhibits signal transduction by multiple types of fibroblast growth factor receptor. J Biol Chem 1992, 267:1470-1476
8. Jaakkola S, Salmikangas P, Nylund S, Partanen J, Armstrong E, Pyrhonen S, Lehtovirta P, Nevanlinna H: Amplification of FGFR4 gene in human breast and gynecological cancers. Int J Cancer 1993, 54:378-382 (Pubitemid 23169673)
9. Ron D, Reich R, Chedid M, Lengel C, Cohen OE, Chan AM, Neufeld G, Miki T, Tronick SR: Fibroblast growth factor receptor 4 is a high affinity receptor for both acidic and basic fibroblast growth factor but not for keratinocyte growth factor. J Biol Chem 1993, 268:5388-5394
10. Ezzat S, Asa SL: FGF receptor signaling at the crossroads of endocrine homeostasis and tumorigenesis. Horm Metab Res 2005, 37:355-360
11. Vainikka S, Partanen J, Bellosta P, Coulier F, Basilico C, Jay M, Alitalo K: Fibroblast growth factor receptor-4 shows novel features in genomic structure, ligand binding and signal transduction. EMBO J 1992, 11:4273-4280
12. Takaishi S, Sawada M, Morita Y, Seno H, Fukuzawa H, Chiba T: Identification of a novel alternative splicing of human FGF receptor 4: soluble-form splice variant expressed in human gastrointestinal epithelial cells. Biochem Biophys Res Commun 2000, 267:658-662 (Pubitemid 30076854)
13. van Heumen WRA, Claxton C, Pickles JO: Fibroblast growth factor receptor-4 splice variants cause deletion of a critical tyrosine. Life 1992, 48:73-78
14. Ezzat S, Zheng L, Zhu XF, Wu GE, Asa SL: Targeted expression of a human pituitary tumor-derived isoform of FGF receptor-4 recapitulates pituitary tumorigenesis. J Clin Invest 2002, 109:69-78
15. Ezzat S, Zheng L, Asa SL: Pituitary tumor-derived fibroblast growth factor receptor 4 isoform disrupts neural cell-adhesion molecule/N-cadherin signaling to diminish cell adhesiveness: a mechanism underlying pituitary neoplasia. Mol Endocrinol 2004, 18:2543-2552
16. Ezzat S, Zheng L, Yu S, Asa SL: A soluble dominant negative fibroblast growth factor receptor 4 isoform in human mcf-7 breast cancer cells. Biochem Biophys Res Commun 2001, 287:60-65 (Pubitemid 32912463)
17. Vainikka S, Joukov V, Wennstrom S, Bergman M, Pelicci PG, Alitalo K: Signal transduction by fibroblast growth factor receptor-4 (FGFR-4): comparison with FGFR-1. J Biol Chem 1994, 269:18320-18326
18. Hart KC, Robertson SC, Kanemitsu MY, Meyer AN, Tynan JA, Donoghue JA: Transformation and Stat activation by derivatives of FGFR1. FGFR3, and FGFR4. Oncogene 2000, 29:3309-3320
19. Johnston CL, Cox HC, Gomm JJ, Coombes RC: bFGF and aFGF induce membrane ruffling in breast cancer cells but not in normal breast epithelial cells: FGFR-4 involvement. Biochem J 1995, 306:609-616
20. Hughes SE: Differential expression of the fibroblast growth factor receptor (FGFR) multigene family in normal human adult tissues. J Histochem Cytochem 1997, 45:1005-1019
21. Thussbas C, Nahrig J, Streit S, Bange J, Kriner M, Kates R, Ulm K, Kiechle M, Hoefler H, Ullrich A, Harbeck N: FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer. J Clin Oncol 2006, 24:3747-3755
22. Zhu X, Asa SL, Ezzat S: Histone-acetylated control of fibroblast growth factor receptor 2 intron 2 polymorphisms and isoform splicing in breast cancer. Mol Endocrinol 2009, 23:1397-1405
23. Zhu X, Asa SL, Ezzat S: Genetic and epigenetic mechanisms down-regulate FGF receptor 2 to induce melanoma-associated antigen A in breast cancer. Am J Pathol 2010, 176:2333-2343
24. Liu W, Cheng S, Asa SL, Ezzat S: The melanoma-associated antigen A3 mediates fibronectin-controlled cancer progression and metastasis. Cancer Res 2008, 68:8104-8112
25. Liu W, Wei W, Winer D, Bamberger AM, Bamberger C, Wagener C, Ezzat S, Asa SL: CEACAM1 impedes thyroid cancer growth but promotes invasiveness: a putative mechanism for early metastases. Oncogene 2007, 26:2747-2758
26. Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, Bignell G, Davies H, Teague J, Butler A, Stevens C, Edkins S, O'Meara S, Vastrik I, Schmidt EE, Avis T, Barthorpe S, Bhamra G, Buck G, Choudhury B, Clements J, Cole J, Dicks E, Forbes S, Gray K, Halliday K, Harrison R, Hills K, Hinton J, Jenkinson A, Jones D, Menzies A, Mironenko T, Perry J, Raine K, Richardson D, Shepherd R, Small A, Tofts C, Varian J, Webb T, West S, Widaa S, Yates A, Cahill DP, Louis DN, Goldstraw P, Nicholson AG, Brasseur F, Looijenga L, Weber BL, Chiew YE, deFazio A, Greaves MF, Green AR, Campbell P, Birney E, Easton DF, Chenevix-Trench G, Tan MH, Khoo SK, Teh BT, Yuen ST, Leung SY, Wooster R, Futreal A, Stratton MR: Patterns of somatic mutation in human cancer genomes. Nature 2007, 446:153-158
27. Taylor JG, Cheuk AT, Tsang PS, Chung JY, Song YK, Desai K, Yu Y, Chen QR, Shah K, Youngblood V, Fang J, Kim SY, Yeung C, Helman LJ, Mendoza A, Ngo V, Staudt LM, Wei JS, Khanna C, Catchpoole D, Qualman SJ, Hewitt SM, Merlino G, Chanock SJ, Khan J: Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models. J Clin Invest 2009, 119:3395-3407
28. Roidl A, Foo P, Wong W, Mann C, Bechtold S, Berger HJ, Streit S, Ruhe JE, Hart S, Ullrich A, Ho HK: The FGFR4 Y367C mutant is a dominant oncogene in MDA-MB453 breast cancer cells. Oncogene 2010, 29:1543-1552
29. Stadler CR, Knyazev P, Bange J, Ullrich A: FGFR4 GLY388 isotype suppresses motility of MDA-MB-231 breast cancer cells by EDG-2 gene repression. Cell Signal 2006, 18:783-794
30. Acevedo VD, Ittmann M, Spencer DM: Paths of FGFR-driven tumorigenesis. Cell Cycle 2009, 8:580-588
31. Koziczak M, Hynes NE: Cooperation between fibroblast growth factor receptor-4 and ErbB2 in regulation of cyclin D1 translation. J Biol Chem 2004, 279:50004-50011
32. da Costa Andrade AV, Parise O Jr, Hors CP, de Melo Martins PC, Silva AP, Garicochea B: The fibroblast growth factor receptor 4 (FGFR4) Arg388 allele correlates with survival in head and neck squamous cell carcinoma. Exp Mol Pathol 2007, 82:53-57 (Pubitemid 46038266)
33. Bange J, Prechtl D, Cheburkin Y, Specht K, Harbeck N, Schmitt M, Knyazeva T, Muller S, Gartner S, Sures I, Wang H, Imyanitov E, Haring HU, Knayzev P, Iacobelli S, Hofler H, Ullrich A: Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele. Cancer Res 2002, 62:840-847
34. Nan H, Qureshi AA, Hunter DJ, Han J: Genetic variants in FGFR2 and FGFR4 genes and skin cancer risk in the Nurses' Health Study. BMC Cancer 2009, 9:172
35. Matakidou A, El Galta R, Rudd MF, Webb EL, Bridle H, Eisen T, Houlston RS: Further observations on the relationship between the FGFR4 Gly388Arg polymorphism and lung cancer prognosis. Br J Cancer 2007, 96:1904-1907
36. Jezequel P, Campion L, Joalland MP, Millour M, Dravet F, Classe JM, Delecroix V, Deporte R, Fumoleau P, Ricolleau G: G388R mutation of the FGFR4 gene is not relevant to breast cancer prognosis. Br J Cancer 2004, 90:189-193
37. Borze I, Juvonen E, Ninomiya S, Jee KJ, Elonen E, Knuutila S: High-resolution oligonucleotide array comparative genomic hybridization study and methylation status of the RPS14 gene in de novo myelodysplastic syndromes. Cancer Genet Cytogenet 2010, 197:166-173
38. Ebert BL, Pretz J, Bosco J, Chang CY, Tamayo P, Galili N, Raza A, Root DE, Attar E, Ellis SR, Golub TR: Identification of RPS14 as a 5q-syndrome gene by RNA interference screen. Nature 2008, 451:335-339
39. Armstrong E, Hastbacka J, Partanen J, Huebner K, Alitalo K: RFLPs in the fibroblast growth factor receptor-4 locus (FGFR4) in 5q33-qter. Nucleic Acids Res 1991, 19:5096
40. Wang ZC, Lin M, Wei LJ, Li C, Miron A, Lodeiro G, Harris L, Ramaswamy S, Tanenbaum DM, Meyerson M, Iglehart JD, Richardson A: Loss of heterozygosity and its correlation with expression profiles in subclasses of invasive breast cancers. Cancer Res 2004, 64:64-71
41. Seitzer N, Mayr T, Streit S, Ullrich A: A single nucleotide change in the mouse genome accelerates breast cancer progression. Cancer Res 2010, 70:802-812
42. Naderi A, Teschendorff AE, Barbosa-Morais NL, Pinder SE, Green AR, Powe DG, Robertson JF, Aparicio S, Ellis IO, Brenton JD, Caldas C: A gene-expression signature to predict survival in breast cancer across independent data sets. Oncogene 2007, 26:1507-1516
43. Blenkiron C, Goldstein LD, Thorne NP, Spiteri I, Chin SF, Dunning MJ, Barbosa-Morais NL, Teschendorff AE, Green AR, Ellis IO, Tavare S, Caldas C, Miska EA: MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype. Genome Biol 2007, 8:R214